Abstract:Background: Adults with acute myeloid leukemia with normal cytogenetics (AML-CN) have variable relapse risks. New mutations correlated with relapse risk are needed. Understanding clonal trajectory of relapse in this setting may improve understanding of leukaemia development. Aims: Interrogate genomic landscape and clone trajectory data in adults with CN-AML and identify new mutations associated with relapse risk. Methods: 333 consecutive, newly-diagnosed adults with CN-AML seen in Peking University Peoples Hospital March, 2006 and April, 2018 were studied. Whole-exome sequencing (WES) was done in 23 subjects with diagnosis, remission and relapse samples. Using these and published data we developed a customized panel of 322 AML-related genes. Diagnostic DNA samples of the remaining 310 subjects were studied and the coding regions or hotspot areas of the 322 genes were sequenced by deep target regional sequencing (TRS). Average effective sequencing depths were 200X (145–265X) for WES and 1500X (1000–1800X) for TRS. Median coverages were 99.9% (77.6, 99.9%) and 99.0% (98.0, 99.5%). Results: We identified 3672 non-synonymous somatic variants in 309 genes by TRS. In 305 subjects ≥5 mutations were identified (98%; 95% confidence interval [CI], 97, 100%), with a median of 13 mutations per subject (range, 2–27; Figure). We identified mutations at 4 new loci including DDX11 in 23 subjects (7%), CYP2F1(4%), NPIPA5 (3%) and MED12 (2%). We then interrogated the impact of DDX11 mutations by matching these subjects with 115 controls according to age (<60/≥60 y), NPM1(Y/N) and FLT3-ITD(Y/N) mutations and WBC (<100/≥100x10E+9/L). In multivariable analyses DDX11 mutation was independently-associated with cumulative incidence of relapse (CIR; Hazard Ratio [HR] = 2.15 [1.12, 4.13]; P = 0.021) and relapse-free survival (RFS; HR = 2.12 [1.03, 4.38];P = 0.042). Other mutations identified included driver genes in the RAS/RTK signaling pathway (27%), chromatin modifier pathway(10%), DNA-methylation pathway (8%), transcription factor pathway (8%), histone methylation pathway (5%), cohesin complex pathway (3%) and the spliceosome pathway (3%). NPM1 was the most frequent mutated gene in our cohort (N = 75; 24% [19, 29%]), followed by FLT3-ITD (N = 64; 21% [16, 25%]) and DNMT3A (N = 59; 19% [15, 23%]). Using triplicate samples from the 23 subjects we identified 3 clonal trajectory patterns: (1) Dominant clone at diagnosis and relapse without new mutations (N = 2); (2) Dominant clone at diagnosis with ≥1 new mutation (N = 13); and (3) evolution from a minor clone detected at diagnosis (N = 8).The clonal trajectory of relapse after chemotherapy was like that posttransplant but the latter was associated with more relapse-specific sub-clones possibly related to intensive pretransplant conditioning.Summary/Conclusion: We identified 4 new mutated genes in AML-CN and show DDX11 mutations correlate with a higher CIR and worse RFS in multivariable analyses. We also detected 3 distinct clonal trajectories which provide insight into mechanisms of relapse after chemotherapy and transplantation and the pathogenesis of AML-CN.

Prospective Study of 174 De Novo Acute Myelogenous Leukemias According to the WHO Classification: Subtypes, Cytogenetic Features and FLT3 Mutations.

Cytogenetic Profile of De Novo Acute Myeloid Leukemia: a Study Based on 1432 Patients in a Single Institution of China

Retrospective Analysis of 59 Cases Flt3-Itd Mutation Positive Acute Myeloid Leukemia

MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Cytogenetic Analysis of 1863 Chineses Patients with Chronic Myeloid Leukemia

FLT3-ITD As a Prognostic Factor for Chinese Patients with Acute Myeloid Leukemia

A novel prognostic scoring model for newly diagnosed FLT3-ITD-positive acute myeloid leukemia

The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China

Comprehensive profile of cytogenetics in 2308 Chinese children and adults with de novo acute myeloid leukemia.

Significant Correlation Between Immunophenotypings And Cytogenetic Features By Analysis Of High Resolution Flow Cytometry With Who Classification In Adult Acute Myeloid Leukemia In China.

Mutation Topography and Risk Stratification for De Novo Acute Myeloid Leukaemia with Normal Cytogenetics and No Nucleophosmin 1 (NPM1) Mutation or Fms‐like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3‐ITD)

An Analysis of 97 Previously Diagnosed De Novo Adult Acute Erythroid Leukemia Patients Following the 2016 Revision to World Health Organization Classification

Clinical features and long-term outcomes of pediatric patients with de novo acute myeloid leukemia in China with or without specific gene abnormalities: a cohort study of patients treated with BCH-AML 2005

Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3-itd Mutation

Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns

Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group.

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years

PF218 DDX11 MUTATIONS AND CLONAL TRAJECTORY PATTERNS IN ADULTS WITH CYTOGENETICALLY-NORMAL ACUTE MYELOID LEUKEMIA

Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

Flt3, Npm1 And Mll Mutations Help Risk Stratification In Pediatric Acute Myeloid Leukemia.